RxDoctor Payments Data

Constantina Tucker, DO

Family Medicine · Schererville, INNPI 1861515447

Payments from drug & device makers

$2,881in general payments, 2019–2025

Across 93 payments — averaging $30.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$976
  • AbbVie$358
  • Johnson & Johnson$341
  • Jazz Pharmaceuticals Inc.$237
  • Sirtex Medical Inc$141
  • Sanofi-aventis U.S. LLC$125
  • plus $703 from 15 others

What the payments were for

  • Food & beverage$2,881100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,881 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$303,140
Medicare patients
591
Services billed
6,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$160,349
FarxigaDapagliflozin Propanediol61$70,805
JanuviaSitagliptin Phosphate39$55,790
EliquisApixaban32$44,689
JardianceEmpagliflozin25$28,745
MounjaroTirzepatide17$26,924
RybelsusSemaglutide12$21,437
XareltoRivaroxaban12$19,738
MyrbetriqMirabegron17$16,024
Breo ElliptaFluticasone/Vilanterol13$13,133
LinzessLinaclotide11$12,284
SynthroidLevothyroxine Sodium87$6,768
Pantoprazole Sodium147$5,138
Atorvastatin Calcium706$4,448
Levothyroxine Sodium563$4,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$976$181,785100 claims
PfizerEliquis$31$44,68932 claims
Boehringer IngelheimJardiance$40$28,74525 claims
Lilly USA, LLCMounjaro$38$26,92417 claims
Johnson & JohnsonXarelto$341$19,73812 claims
AbbVieLinzess, Synthroid$358$19,05398 claims
Astellas Pharma US IncMyrbetriq$18$16,02417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Schererville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →